As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Leerink notes that Syndax (SNDX) has disclosed topline pivotal data for menin-MLL inhibitor revumenib in NPM1m acute leukemia, which the firm ...

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been given a consensus recommendation of ...

SNDX has been the topic of a number of other research reports. HC Wainwright upped their price objective on Syndax Pharmaceuticals from $45.00 to $47.00 and gave the stock […] Skip to main content ...

On Wednesday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $21.35 which represents a slight increase of $1.66 or 8.43% from the prior close of $19.69. The stock ...